Navigation Links
Endo Pharmaceuticals Announces Leadership Change at HealthTronics Subsidiary: Appoints Kelly Huang, Ph.D. New President
Date:8/22/2011

CHADDS FORD, Pa., Aug. 22, 2011 /PRNewswire/ -- Endo Pharmaceuticals (Nasdaq: ENDP) announced today the appointment of Kelly Huang, Ph.D., to the position of President, HealthTronics Inc., effective Aug. 29, 2011. HealthTronics, an Endo subsidiary, is a leading U.S. provider of urological products and services based in Austin, Texas.

Huang will take over leadership from current HealthTronics Group President James Whittenburg, who is staying through the remainder of the year to effect a seamless transition as HealthTronics continues to provide exceptional urological products and services in improving patient care. Whittenburg joined HealthTronics in 2004, was appointed President and CEO in 2007 and became an Endo Group President in July 2010 with the acquisition of HealthTronics, Inc.

Prior to joining HealthTronics, Dr. Huang held the role of Vice President of Research & Development at Neutrogena, where he was also a member of the global Management Board.  Prior to Neutrogena, Dr. Huang established and headed the Molsaic Internal Venture, a startup sponsored by Johnson & Johnson's Development Corporation. Prior to Molsaic, Dr. Huang held leadership positions within Johnson & Johnson's Consumer business, which included spending two years in Paris, France, that drove innovation globally.

"I am very pleased to announce Kelly's appointment to lead our important HealthTronics subsidiary," said David Holveck, president and chief executive officer of Endo Pharmaceuticals. "Kelly brings a wealth of experience leading global businesses through the integration of scientific, consumer and professional insights and creating value by putting the customer and patient at the center. Kelly's experiences and skills will be invaluable to Endo's continued transformation to provide integrated healthcare solutions to patients, payers and providers, as well as Healt
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant Pharmaceuticals Completes Acquisition of Sanitas Group
2. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
3. Valeant Pharmaceuticals Announces Resignation of Michael Van Every From Valeants Board of Directors
4. Endo Pharmaceuticals Announces Termination of Collaboration with Grunenthal for the Development of Axomadol
5. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
6. Access Pharmaceuticals Provides Second Quarter Update on MuGard Commercial Activities
7. Janssen Pharmaceuticals, Inc. Launches Online Tools on PrescribeResponsibly.com
8. Lotus Pharmaceuticals Announces Second Quarter Fiscal 2011 Financial Results
9. Omthera Pharmaceuticals, Inc. Initiates Phase III ESPRIT Trial of Add-on Epanova™ to Statin Therapy in Patients with Hypertriglyceridemia
10. Pacira Pharmaceuticals, Inc. to Present at Wedbush Securities 2011 Life Sciences Management Access Conference
11. Robert Hoffman to Rejoin Arena Pharmaceuticals as Vice President, Finance and Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... DALLAS , September 2, 2014 ... Chromatography Column Market by Type (Empty, Pre-packed, Analytical, Preparative), by Material ... Flash Chromatography, UFLC), TLC,SFC] - Forecast to 2018", published by ... Million in 2013. It is poised to grow at ... Million by 2018. Browse 90 market ...
(Date:9/2/2014)... 2014 Particle Sciences, the leading CDMO for ... development and manufacturing capabilities with the addition of a ... Particle Sciences, Associate Director Clinical Production, "The company has ... square footage, equipment and staff across the board, all ... has over 6000ft 2 of operating cleanroom and ...
(Date:9/2/2014)... , Sept. 2, 2014 /PRNewswire-iReach/ -- Ortho Development® ... Alpine™ Hip Stem, the latest addition to its ... Stem is intended for use in total hip ... http://photos.prnewswire.com/prnh/20140830/141676 Alpine was ... stem philosophy. ODEV,s engineers worked closely with a ...
Breaking Medicine Technology:Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4Particle Sciences Expands Drug Eluting Device Capabilities and Overall Clinical Trial Manufacturing Resources 2Ortho Development Receives FDA Clearance for Alpine Hip Stem 2
... 15 VION,PHARMACEUTICALS, INC. (Nasdaq: VION ) today ... to the pivotal Phase II trial of its lead ... novo poor-risk acute myelogenous leukemia (AML). Alan Kessman, ... reached this milestone in the pivotal Phase II trial ...
... Study to Explore the Efficacy of Novel Proteasome Inhibitor ... Patients with Relapsed and Refractory Multiple Myeloma, SOUTH ... Multiple Myeloma Research Consortium (MMRC) and Proteolix, Inc. today,announced ... Phase 2,clinical trial to study Proteolix,s potent and selective ...
Cached Medicine Technology:Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 2Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 3Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML 4The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 2The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 3The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma 4
(Date:9/2/2014)... 2014 Today, Therapy Changes ... for Me?” The guide outlines common questions an individual ... addition to common types of groups an individual can ... from the interventions of the therapist, but also from ... group members,” says Rochelle Perper, Ph.D. and founder of ...
(Date:9/2/2014)... 02, 2014 The exciting information sessions ... professionals Carey Lewis and Bob Wiley. The ... those who have the desire to illuminate entertainment with ... performers could be invited to join the Bridge ... NC – Saturday, Sept. 6, Charlotte Convention Center, 501 ...
(Date:9/2/2014)... Las Vegas, NV (PRWEB) September 02, 2014 ... a leading provider of “Cloud Based” Medical Practice Business ... and a provider of Digital Cyber Security solutions for ... was recently interviewed on the trading floor of the ... Flynn. Mr. DeLaGarza stated that we are very ...
(Date:9/2/2014)... 02, 2014 On August 30, 2014, ... titled “Why You Should Wash Your Face .” ... the global population breathes air considered polluted by the ... lodge in the skin’s pores destroying its natural oils. ... free radicals that may cause cell damage, redness, ...
(Date:9/2/2014)... in California, the percentage undergoing a double mastectomy increased ... not associated with a lower risk of death than ... the September 3 issue of JAMA . The ... one breast was associated with a higher risk of ... , Randomized trials have demonstrated similar survival for patients ...
Breaking Medicine News(10 mins):Health News:Actors, Models and Talent for Christ Auditions Are Set for Charlotte and Omaha on Saturday, September 6, 2014 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 2Health News:Cloud Medical Doctor Software Corporation's CEO Interviewed by the Price Futures Group 3Health News:Simon Ourian, Kim Kardashian’s Doctor: Air Pollution May Be Aging Your Skin 2Health News:Increase seen in use of double mastectomy 2Health News:Increase seen in use of double mastectomy 3
... written about health care disparities between Latinos and non-Latino whites, ... same disparities from the perspective of the patient, in terms ... But how do the physicians feel about ... face in treating Latino patients, compared with physicians whose patients ...
... by helicopter, an expensive choice that may not impact patient ... and time is of the essence, helicopter transport is generally ... ground ambulance, but a paper published today in the online ... that the actual times to treatment for patients transported by ...
... HealthDay Reporter , WEDNESDAY, Oct. 12 (HealthDay ... for patients with a condition known as Barrett,s esophagus ... a large new Danish study suggests. Analyzing records ... determined that those with Barrett,s esophagus -- a disorder ...
... By Amanda Gardner HealthDay Reporter , WEDNESDAY, Oct. 12 ... marijuana run more than twice the risk of crashing compared to ... if the driver has also been drinking alcohol. The ... Reviews believe the findings are especially relevant in light of ...
... , WEDNESDAY, Oct. 12 (HealthDay News) -- Black ... colon cancer have worse overall and recurrence-free survival rates than ... from nearly 15,000 black and white colorectal cancer surgery patients ... America between 1977 and 2002. All the patients received the ...
... WEDNESDAY, Oct. 12 (HealthDay News) -- The death toll from ... risen to 23, and a total of 116 people have ... Control and Prevention reported late Wednesday. The agency said ... 14, more cases might still emerge since Listeria monocytogenes ...
Cached Medicine News:Health News:Physicians treating Latinos have high hurdles to jump, study shows 2Health News:Interfacility helicopter ambulance transport of neurosurgical patients 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 2Health News:Esophageal Cancer Risk Less Dire for Certain Patients: Study 3Health News:Pot Smoking May More Than Double Crash Risk 2Health News:Pot Smoking May More Than Double Crash Risk 3Health News:Blacks Fare Worse Than Whites After Colon Cancer Surgery 2Health News:Death Toll From Cantaloupe-Linked Listeria Outbreak Now Stands at 23 2
... Lyra-i system combines the longest available wavelength ... maximize patient safety and efficacy. The unique ... the therapeutic range to all targeted structures. ... ensuring patient safety. All Lyra-I patients are ...
... The Company's Aura-i Laser System is ... designed for office-based procedures. Its unique, integrated ... benign vascular, including telangiectasia on the leg ... leg veins. It can also be used ...
Surgisis Inguinal Hernia Matrix is implanted to reinforce soft tissues in the inguinal floor to repair inguinal hernias. Supplied sterile in peel-open packages. Intended for one-time use....
Used for implantation to reinforce soft tissue in the repair of a hernia or body wall defect. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: